Vorapaxar in Acute Limb Ischemia

Original Title: Acute Limb Ischemia and Outcomes With Vorapaxar in Patients with Peripheral Artery Disease: Results From TRA2°P-TIMI 50. Reference: Marc P. Bonaca et al. Circulation. 2016 Mar 8;133(10):997-1005.

 

Patients with peripheral artery disease have a high risk of acute limb ischemia, an event that may result in the loss of the affected limb.

This study addresses the causes, sequelae and predictors of acute limb ischemia and test the hypothesis that PAR-1 antagonism with vorapaxar reduce its incidence.

The TRA2°P-TIMI 50 was a randomized, double blind, placebo controlled trial that tested Vorapaxar in stable patients, including 3787 with a history of symptomatic peripheral arterial disease. Acute limb ischemia was pre-specified in the study.

A total of 150 acute limb ischemia events in 108 patients occurred during follow up(3.9% to 3 years, 1.3% annualized).

In patients with symptomatic peripheral artery disease, smoking, prior revascularization and ankle-brachial index were predictors of acute limb ischemia.

Most of the acute ischemia events were due to femoropopliteal surgical graft thrombosis (56%), followed by native vessel in situ thrombosis (27%).

Stent thrombosis and thromboembolism caused acute limb ischemia in 13% and 5% respectively. Amputation occurred in 17.6% of acute limb ischemia patients. Vorapaxar reduced the chance of acute ischemia by 41% (HR 0.58, 95% CI 0.39 to 0.86; p=0.006) and this efficacy was consistent across acute ischemia etiology.

Conclusion
In selected patients with symptomatic peripheral artery disease with no atrial fibrillation, the rate of acute limb ischemia is 1.3% per year and is more often caused by acute thrombosis of a surgical bypass graft and in situ thrombosis. Vorapaxar reduces acute limb ischemia across all etiologies.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....